Changes in Sarcopenia and Incident Depression in Prospective Cohorts
Abstract
Background: Previous studies have confirmed an association between sarcopenia and depression but were mostly based on single baseline assessments, ignoring dynamic changes in sarcopenia status. This study aimed to investigate the association between changes in sarcopenia status and incident depression risk. Methods: Data were sourced from the China Health and Retirement Longitudinal Study (CHARLS). Sarcopenia status was classified as non-sarcopenia, possible sarcopenia, or sarcopenia according to AWGS 2019 criteria. Changes in status were defined by comparing assessments at baseline (2011) and two years later (2013). Depression was assessed using the CESD-10 (score ≥10). Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Results: Participants who progressed from non-sarcopenia to possible sarcopenia or sarcopenia had a higher risk of depression than those who remained non-sarcopenic (HR 1.30, 95% CI 1.14-1.47). Conversely, participants who recovered from sarcopenia had a lower risk of depression than those with persistently stable sarcopenia (HR 0.65, 95% CI 0.45-0.94). Conclusions: Changes in sarcopenia status are differentially associated with the risk of incident depression. The progression of sarcopenia status is associated with an increased risk of incident depression, whereas recovery from sarcopenia is linked to a reduced risk.
Read the paper
Related studies
- Promising Sources of Plant-Derived Polyunsaturated Fatty Acids: A Narrative Review
- Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials
- Effect of omega-3 fatty acids on cognition: an updated systematic review of randomized clinical trials
- The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus: A narrative review
- Paucity of evidence for a relationship between long-chain omega-3 fatty acid intake and chronic obstructive pulmonary disease: a systematic review
- Omega-3 fatty acid nanocarriers: Characterization and potential applications
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.